Patients featured are compensated by ViiV Healthcare.
What do the studies say about DOVATO?
DOVATO has about 4 years of clinical study results (from Study 3). Multiple studies (Study 3, and Studies 1 & 2) have shown how effective and safe DOVATO can be for people living with HIV. See details below. Your results may vary.
Who took part in clinical trials?
DOVATO was studied in multiple clinical trials among diverse groups, including:
STUDY 3 FOLLOWED PEOPLE WHO SWITCHED TO DOVATO AFTER ALREADY BEING UNDETECTABLE*
One study included 741 adults who were already undetectable with their previous HIV treatment.†
369 people switched to DOVATO, and 372 people stayed on their previous HIV treatment and were followed for ~3 years.
DOVATO WAS PROVEN TO HELP PEOPLE ALREADY ON TREATMENT STAY UNDETECTABLE
as effectively as an HIV regimen containing 3 or 4 medicines.†
During the ~3-year period, no one who switched to DOVATO developed HIV resistance.
SIDE EFFECTS
In this study, 15% of people taking DOVATO versus 5% taking a 3- or 4-drug regimen† experienced side effects during a ~3-year period. The majority of side effects were mild in severity.
The most common side effects were:
-
Taking DOVATO: weight gain (3%), trouble sleeping (2%), nausea (1%), diarrhea (1%), and anxiety (1%).
- Taking a 3- or 4-drug regimen†: weight gain (2%), nausea (<1%), diarrhea (<1%), and anxiety (<1%).
*Undetectable means the amount of HIV in the blood is below the level that can be measured by a lab test.
†Tenofovir alafenamide (TAF)–containing 3- or 4-drug regimen.
AFTER THE ~3-YEAR PERIOD, PEOPLE ON DOVATO WERE STUDIED FOR ~1 MORE YEAR‡
At ~4 years, an evaluation was done on how well DOVATO worked and its side effects.
‡People who were undetectable on a 3- or 4-drug regimen switched to DOVATO, and effectiveness and safety were evaluated for ~1 more year.
IN A STUDY OF ADULTS WITH HIV WHO SWITCHED TO DOVATO AT THE START OF THE STUDY:
SIDE EFFECTS WERE SIMILAR TO THE FIRST ~3 YEARS OF THE STUDY
PROVEN EFFECTIVE IN PEOPLE NEW TO HIV TREATMENT
Two combined studies included 1,433 adults new to HIV-1 treatment.
716 people started DOVATO and 717 people started a 3-drug HIV treatment† and were followed for ~3 years.
In two combined studies,
DOVATO WAS PROVEN TO HELP PEOPLE NEW TO TREATMENT REACH AND STAY UNDETECTABLE
(less than 50 copies per mL) as effectively as a regimen containing 3 medicines.†
One patient taking DOVATO developed HIV resistance during a ~3-year period.
The majority of people who took DOVATO reached and remained undetectable for ~3 years
Side Effects
Across the two combined studies, 20% of patients taking DOVATO versus 27% taking a 3-drug regimen† experienced side effects during a ~3-year period.
The most common side effects were:
- Taking DOVATO: headache (3%), nausea (2%), diarrhea (2%), trouble sleeping (2%), tiredness (2%), anxiety (2%), and dizziness (1%).
- Taking a 3-drug regimen†: headache (4%), nausea (6%), diarrhea (3%), trouble sleeping (3%), tiredness (2%), anxiety (1%), and dizziness (2%).
†Dolutegravir + tenofovir disoproxil fumarate/emtricitabine.
PMUS-DLLWCNT260009